7-(5-chloro-2-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 376592-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-(5-chloro-2-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 7-(5-chloro-2-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxylic acid
• CAS: 376592-48-2
• 化学式: C₁₆H₁₀ClNO₄
• 分子量: 315.713
• InChiKey: FJHNJIASWYLEIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Thrombopoietin mimetics
  申请人：——

  公开号：US20040019190A1

  公开（公告）日：2004-01-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy- 1 -azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备目前发明的化合物的新工艺和中间体。还发明了一种治疗血小板减少症的方法，包括给予需要的哺乳动物，包括人类，有效量的选择性羟基-1-偶氮苯衍生物。
• THROMBOPOIETIN MIMETICS
  申请人：Duffy Kevin J.

  公开号：US20130078213A1

  公开（公告）日：2013-03-28

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

  本发明涉及非肽类TPO类似物的发明。本发明还涉及用于制备目前发明的化合物的新型过程和中间体。本发明还涉及一种治疗血小板减少症的方法，包括在需要的哺乳动物（包括人类）中给予所选的羟基-1-偶氮苯衍生物的有效量。
• EP1294378A4
  申请人：——

  公开号：EP1294378A4

  公开（公告）日：2004-01-28
• [EN] THROMBOPOIETIN MIMETICS<br/>[FR] MIMIQUES DE THROMBOPOIETINE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2001089457A2

  公开（公告）日：2001-11-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.